Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label single-arm study of idarucizumab for urgent reversal of dabigatran anticoagulation in pediatric patients
MOH_2018-10-02_003591Phase 3Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2018
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of idarucizumab in Bleeding, sponsored by Boehringer Ingelheim. Started Jul 2018; status: active, not recruiting.
02
Drugs
idarucizumab
03
Conditions
Bleeding
Beyond the preview
Go deeper on MOH_2018-10-02_003591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-10-02_003591.